Summary of Significant Accounting Policies - Contingent Consideration (Details) - USD ($) $ in Thousands |
9 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Business Combination, Contingent Consideration [Line Items] | ||||
| Change in the estimated fair value of acquisition-related contingent consideration | $ 4,570 | $ 0 | $ (99) | |
| Sherlock Biosciences | ||||
| Business Combination, Contingent Consideration [Line Items] | ||||
| Beginning balance | 22,910 | |||
| Additions | 233 | |||
| Change in the estimated fair value of acquisition-related contingent consideration | $ 4,600 | 4,570 | ||
| Ending balance | $ 27,713 | $ 22,910 | ||
| X | ||||||||||
- Definition Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Additions No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|